

Written Testimony

Re: Ohio House Agriculture Committee Hearing HB587

Honorable Chair Klopfenstein, Vice Chair Newman, Ranking Member Miller and members of the House Agriculture Committee, good day and thank you for the opportunity to speak.

My name is Dr. Kirsten Smith, and I am providing testimony as an interested party, although I am in opposition to aspects of HB587 which would effectively prohibit the sale of 7-hydroxymitragynine (7-OH) products.

I have studied kratom and opioids since 2017, with my work beginning in earnest during my 4-year postdoctoral fellowship at the National Institute on Drug Abuse (NIDA). Physical dependence and substance use disorders related to kratom and opioids have comprised much of my work, which includes over 90 peer-reviewed publications (as attested to on my CV).

After my postdoc, my research on kratom continued at Johns Hopkins University where I had two clinical trials on kratom and pilot projects examining 7OH use. I regularly advise clinical groups and speak about 7-OH to national academic consortiums.

I was actually one of the first scientists to raise concerns about 7-OH and am among the few clinical researchers and licensed clinicians to have collected data on 7-OH. In 2021, not yet having collected data and not yet having fully reviewed the preclinical literature, I assumed that 7-OH would become a public health concern. That concern has, ultimately, not been validated.

This initial panic was similar to a decade ago: When kratom extracts began proliferating, I and others voiced concerns around toxicity and addiction, yet our fears were not realized.

The FDA has long promoted policies around kratom that were and are not supported by data; the same is now occurring for kratom-derivatives, such as 7-OH. This has caused confusion about kratom and its constituent alkaloids, including mitragynine and 7-OH.

I speak with addiction providers regularly and I can attest to the fact that kratom and 7-OH are among their caseloads. Of the approximately 15 cases on 7-OH products that have been published over the past 3 years none have shown

indicators of harm characteristic of typical opioid analgesics, including respiratory depression.

In 14 cases discussing 7-OH and kratom-related substance use disorder, the presentations were ambiguous—often will polysubstance use. But with respect to 7-OH withdrawal, presentations were *mild* as scored on the Clinical Opiate Withdrawal Scale. Only one timepoint showed a transient moderate rating. In several cases, the patient had a severe substance use disorder for kratom leaf powder (not 7OH), yet even these cases are outliers.

Cases related to toxicity are likewise uncommon, numbering in the several dozens and often with confounding health factors.

The 7-OH consumers I have studied express desire for greater regulation of kratom and 7-OH, seeing each with their own unique risk-benefit profiles. Nearly 80% of the 7-OH consumers we collected data for believed that 7-OH should remain legal but with regulations, including sales that are restricted to venues 21 and up for entry, product testing, wholesome brand names, clear labeling that, among other things, would distinguish 7-OH from kratom leaf, restrictions on formulations that are not oral (such as sublingual, intranasal), serving size caps, and prohibition of sales near schools or college campuses.

Kratom and 7OH are not opioids. They demonstrate highly atypical opioidergic and other activity. They are not “gas station heroin.” These are false, misleading, and unhelpful statements which confuse needed policy conversations geared at regulating-- rather than prohibiting-- products that Ohio adults choose to consume.

Any bill that would essentially ban an entire class of 7-OH products is assuming that all molecules are equal, and that 7-OH, as a constituent and metabolite of mitragynine, has a demonstrated pharmacology in humans that is riskier than that of other kratom constituents. That is a disingenuous premise without data to support it.

The preponderance of clinical data do not show that kratom and 7-OH are public health threats, particularly within this relative risk landscape in which we live.

For most, the use of each has been geared towards functioning and wellbeing, including use to relieve pain, improve mood, gain energy, and reduce use of harmful substances.

And that is why I am here: kratom and 7-OH consumers are a highly self-selected group and if it is not 7-OH they purchase, it will be whatever replaces it. For some, it will be a return to illicit drugs. For others, it will diminish their ability to exercise autonomy in their decision-making about alternative wellness products.

The complicating factors which gave rise to a demand in kratom and 7-OH predates their entry into commerce. That demand will not end with the effective prohibition of 7-OH.

I ask that you to listen to data and commonsense and pass regulation for all kratom-derived products, including those containing 7-OH as their primary ingredient.

To conclude, I want to emphasize that kratom and 7-OH are complex, both pharmacologically and in terms of human consumption.

Most of us want matters to be good or bad or black or white, but that is not how this works, particularly with respect to abuse liability or addiction potential.

Thank you for your time and I am happy to answer any questions you may have.

Kirsten Smith, Ph.D., L.M.S.W.

CURRICULUM VITAE

Kirsten E. Smith

Kirsten E. Smith

March 2026

Contact Information

Phone: 310-986-7475

E-mail: dialsquarellc@pm.me

Education and Training

- 2010-2014 Bachelor of Social Work, minors History and Psychology. University of Kentucky, Lexington, KY
Summa Cum Laude
- 2014-2015 Master of Social Work, University of Kentucky. Lexington, KY. Summa Cum Laude
Primary mentor, Michele Staton, Ph.D.
- 2015 Postbaccalaureate Independent Study. University of Kentucky, Department of Behavioral Science
Lexington, KY
Primary mentor Robert J. Walker, M.S.W.
- 2016-2019 Doctor of Philosophy in Social Work, Kent School of Social Work. Louisville, KY
Co-mentors Robert J. Walker, M.S.W., Michele Staton, Ph.D., Martin T. Hall, Ph.D.
- 2019-2023 Postdoctoral Fellowship, National Institute on Drug Abuse Intramural Research Program. Baltimore, MD
Primary mentor David. H. Epstein Ph.D., co-mentor Lorenzo Leggio, M.D., Ph.D.

Professional Experience

- 2013 Clinical Internship, Hope Center Men's Recovery Program. Lexington, KY
- 2013 Undergraduate Clinical Practicum, Chrysalis House. Lexington, KY
- 2014 Undergraduate Community Practicum, United Way of the Bluegrass. Lexington, KY
- 2014-2015 Graduate Clinical Practicum, Hope Center Men's Recovery Program. Lexington, KY
- 2015-2016 Research Assistant, University of Kentucky College of Medicine. Lexington, KY
- 2015-2016 Senior Data Coordinator, University of Kentucky Center on Drug and Alcohol Research. Lexington, KY
- 2016-2018 Research Assistant, University of Louisville. Louisville, KY
- 2018-2019 Data Coordinator/Analyst, University of Kentucky Center on Drug and Alcohol Research. Lexington, KY
- 2019-2023 NIDA IRP Postdoctoral Training Fellow, Translational Addiction Medicine Branch. Baltimore, MD
- 2023-2025 Assistant Professor, Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Science, Behavioral Pharmacology Research Unit, Baltimore, MD
- 2026-present Consultant, Dial Square LLC, Kansas City, KS

PUBLICATIONS

*Designates corresponding author status, underline designates a mentee, †designates equal contribution authorship

Original Research

1. Dickson MF, Staton-Tindall M, **Smith KE**, Leukefeld C, Webster JM, and Oser CB (2017) A Facebook follow-up strategy for rural drug-using women. *The Journal of Rural Health*, 33, 250-256
2. **Smith KE***, Bunting A, Staton M, Walker JR, Shalash S, Winston E, and Pangburn K (2017) Examination of synthetic cannabinoid and cathinone use in drug-using offender sample 2013-2015. *Journal of Psychoactive Drugs*, 49, 436-445
3. **Smith KE*** and Lawson T (2017) Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. *Drug and Alcohol Dependence*, 180, 340-348

4. **Smith KE*** (2018) Prevalence and correlates of electronic cigarette use among a clinical sample of polysubstance users in Kentucky: Long live the cigarette? *Substance Use and Misuse*, 54, 225-235
5. **Smith KE*** and Staton M (2019) Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs? *Substance Abuse*, 40, 160-169
6. **Smith KE***, Bunting AM, Golder S, Hall MT, Higgins GE, and Logan TK (2019) Prevalence and correlates of disability among a sample of victimized women on probation and parole. *Journal of Correctional Healthcare*, 33, 250-256
7. **Smith KE*** and Stoops WW (2019) Synthetic cathinone use among a sample of polysubstance users: Indirect indicator of indiscriminate drug taking or preferred drug of abuse? *Journal of Drug Issues*, 49, 369-386
8. **Smith KE***, Bunting A, Walker JR, Hall MT, Grundmann O, and Castillo O (2019) Non-prescribed buprenorphine use mediates the relationship between recent heroin and kratom use among a sample of polysubstance users. *Journal of Psychoactive Drugs*, 51, 311-322
9. Walker JR, Staton M, Victor G, **Smith KE**, and Godlaski T (2019) Fidelity in evidence-based practices in jail settings. *Federal Probation*, 83, 45-51
10. Bath R, Bucholz T, Buross AF, Singh D, **Smith KE**, Veltri CA, and Grundmann O. (2020) Self-reported health diagnoses and demographic correlates with kratom use: Results from an online survey. *Journal of Addiction Medicine*, 14, 244-252
11. **Smith KE***, Tillson MD, Staton M, and Winston EM (2020) Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky. *Drug and Alcohol Dependence*, 208, 107837
12. **Smith KE***, Archuleta A, Staton M, and Winston EM (2020) Risk factors for heroin use following release from jail or prison in adults in a Central Appalachian state between 2012-2017. *The American Journal of Drug and Alcohol Abuse*, 46, 485-497
13. Garcia-Romeu A, Cox DJ, **Smith KE**, Dunn KE, and Griffiths RR (2020) Kratom (*Mitragyna speciosa*): User demographics, use patterns, and implications for the opioid epidemic. *Drug and Alcohol Dependence*, 208, 107849
14. Singh D, Brown PN, Cinosi E, Corazza O, Henningfield JE, Garcia-Romeu A, McCurdy CR, McMahon LR, Prozialeck WC, **Smith KE**, Swogger MT, Veltri C, Walsh Z, and Grundmann O (2021) Current and future potential impact of COVID-19 on kratom (*Mitragyna speciosa* Korth.) supply and use. *Frontiers in Psychiatry*, 11, 1355
15. Strickland JC, Stoops WW, Dunn KE, **Smith KE**, and Havens JR (2021) The continued rise of methamphetamine use among people who use heroin in the United States, 2015-2019. *Drug and Alcohol Dependence*, 225, 108750
16. Singh D, Narayanan S, Vicknasingam B, Prozialeck WC, **Smith KE**, Corazza O, Henningfield JE, and Grundmann O (2021) The use of kratom (*Mitragyna speciosa* Korth.) among People who co-use heroin and methamphetamine in Malaysia. *Journal of Addiction Medicine*
17. **Smith KE***, Strickland JC, Rogers JM, and Epstein DH (2021) When obscurity becomes trend. Social-media descriptions of tianeptine use and associated atypical drug use. *American Journal of Drug and Alcohol Abuse*, 1-12
18. Burgess-Hull AJ, **Smith KE**, Schriefer D, Panlilio LV, Epstein DH, and Preston KL (2021) Longitudinal patterns of momentary stress during outpatient opioid agonist treatment: A growth-mixture model approach to classifying patients. *Drug and Alcohol Dependence*, 226, 108884
19. **Smith KE***, Rogers JM, Dunn KE, Garcia-Romeu A, Grundmann O, Swogger MT, Epstein DH (2021) Social, psychological, and substance use characteristics of adults who use kratom in the United States: Findings from an online crowdsourced study. *Experimental and Clinical Psychopharmacology*.
20. **Smith KE***, Rogers JM, Schriefer D, Grundmann O (2021) Therapeutic benefits with caveats?: Analyzing social media to understand the complexities of kratom use. *Drug and Alcohol Dependence*, 226, 108879
21. Rogers JM, **Smith KE**, Strickland JC, Epstein DH (2021) Kratom use in the US: both a non-metro regional phenomenon and a White middle-class phenomenon? Evidence from NSDUH 2019 and an online convenience sample. *Frontiers in Pharmacology*, 12, 789075
22. Pope ND, Baldwin PK, Gibson A, and **Smith KE** (2022) Becoming a caregiver: Experiences of young adults moving into family caregiving roles. *Journal of Adult Development*, 29, 147-158
23. Grundmann O, Veltri CA, Morcos D, Knightes D, **Smith KE**, Rogers JM (2022). How essential is kratom availability and use during COVID-19? Use pattern analysis based on survey and social media data. *Substance Abuse*, 43, 865-877
24. Bertz JW, **Smith KE**, Panlilio L, Stull SW, Reamer D, Murville-Sullivan M, Holtyn AF, Toegel FM, Epstein DH, Phillips KA and Preston KL (2021) Quality of life during a randomized trial of a therapeutic-workplace intervention for heroin dependence: Web-based mobile assessments reveal effects of drug abstinence and access to paid work. *Drug and Alcohol Dependence Reports*, 100011
25. **Smith KE***, Rogers JM, Strickland JC (2021) Associations of lifetime nonmedical opioid, methamphetamine, and kratom use within a nationally representative US sample. *Journal of Psychoactive Drugs*, 1-11
26. Panlilio LV, Lee A, **Smith KE**, Epstein DH (2022) Were self-described introverts “immune” to increased drug use and entrapment during the pandemic? *Drug and Alcohol Dependence Reports*, 2, 100024

27. **Smith KE***, Dunn KE, Rogers JM, Garcia-Romeu A, Schriefer D, Strickland JC, Epstein DH (2022) Assessment of Kratom Use Disorder and withdrawal among an online convenience sample of US adults. *Journal of Addiction Medicine*, 16, 666-670
28. Grundmann O, Veltri C, Morcos D, Knightes, D, **Smith KE**, Singh D, Corazza O, Cinosi E, Martinotti G, Walsh Z, Swogger MT (2022) Exploring the self-reported motivations of kratom (*Mitragyna speciosa* Korth.) user: A cross-sectional investigation. *The American Journal on Drug and Alcohol Abuse*, 1-12
29. **Smith KE***, Rogers JM, Dunn KE, Grundmann O, McCurdy CR, Schriefer D, Epstein DH (2022) Searching for a signal: Self-reported kratom dose-effect relationships among a US sample of adults with history of regular kratom use. *Frontiers in Pharmacology*, 445
30. Swogger MT, **Smith KE**, Garcia-Romeu A, Grundmann O, Veltri C, Henningfield J, Bursch L (2022) Understanding kratom use: A guide for healthcare providers. *Frontiers in Pharmacology*, 13
31. Burgess-Hull A, **Smith KE**, Panlilo LV, Schriefer D, Preston K, Alter A, Yeager C, Chizmar T, Delbridge T, Zamore K, Beeson J, Epstein DH (2022) Nonfatal opioid overdoses before and after Covid-19: Regional variation in rates of change. *PLoS One*, 17, e0263893
32. Bertz J, Panlilio LV, Stull SW, **Smith KE**, Reamer D, Holtyn AF, Toegel F, Kowalczyk WJ, Phillips KA, Epstein DH, Silverman K, Preston KL (2022) Being at work improves stress, craving, and mood for people with opioid use disorder: Ecological momentary assessment during a randomized trial of experimental employment in a contingency-management-based therapeutic workplace. *Behavior Research and Therapy*, 152, 104071
33. **Smith KE***, Dunn KE, Rogers JM, Grundmann O, McCurdy CM, Garcia-Romeu A, Schriefer D, Swogger M, Epstein DH (2022) Kratom use as more than a “self-treatment. *The American Journal on Drug and Alcohol Abuse*, 48, 684-694
34. Strickland JC, Marks KR, **Smith KE**, Ellis JD, Hobelmann JG, Huhn AS (2022) Patient perceptions of higher-dose naloxone nasal spray for opioid overdose. *International Journal of Drug Policy*, 106, 103751
35. Pont-Fernandez S, Kheyfets M, Rogers JM, **Smith KE**, Epstein DE (2022) Kava (*Piper methysticum*) in the United States: The quiet rise of a substance with often subtle effects. *The American Journal on Drug and Alcohol Abuse*, 1-12
36. Grundmann O, Veltri CA, Morcos S, **Smith KE**, Singh D, Corazza O, Cinosi E, Martinotti G, Walsh Z, Swogger MT (2022) Correlations of kratom (*Mitragyna speciosa* Korth.) use behavior and psychiatric conditions from a cross-sectional survey. *Experimental and Clinical Psychopharmacology*
37. Rogers JM, **Smith KE**, Schriefer D, Epstein DH (2022) For better or worse: Self-reported changes in kratom use as a result of the Covid-19 pandemic. *Substance Abuse: Research and Treatment*
38. **Smith KE***, Rogers JM, Feldman JD (2023) Kratom’s emergence and persistence within the US polydrug epidemic. *Current Addiction Reports*
39. Feldman JD, Schriefer D, **Smith KE***, Weiss ST, Butera G, Dunn KE, Grundmann O, McCurdy CR, Singh D, Epstein DH (2023) Omissions, ambiguities, and underuse of causal assessment tools: A systematic review of case reports on patients who use kratom. *Current Addiction Reports*
40. **Smith KE***, Feldman JD, Schriefer D, Weiss ST, Grundmann O, Dunn KE, Singh D, McCurdy CR, Butera G, Epstein DH (2023) Diagnostic ambiguities and underuse of clinical assessment tools: A systematic review of case reports on kratom addiction and physical dependence. *Current Addiction Reports*
41. Hill K, Gibson S, Grundmann O, **Smith KE**, Ballard J, Stanciu CN (2023) Evaluating health information provided to kratom consumers by Good Manufacturing Practice-qualified vendors. *Substance Abuse, Treatment, Prevention, and Policy*
42. **Smith KE***, Feldman JD, Dunn KE, McCurdy CR, Weiss ST, Grundmann O, Garcia-Romeu A, Nichols J, Epstein DH (2023) Examining the paradoxical effects of kratom: A narrative inquiry. *Frontiers in Pharmacology*
43. **Smith KE***, Feldman JD, Dunn KE, McCurdy CR, Grundmann O, Garcia-Romeu A, Panlilio LV, Rogers JM, Sharma A, Pont-Fernandez S, Kheyfets M, Epstein DH (2023) Novel methods for the remote study of emerging substances: Application to kratom. *Experimental and Clinical Psychopharmacology*
44. Ware O, Strickland JC, **Smith KE**, Blakey SM, Dunn KE (2023) Factors associated with high-risk substance use in persons receiving psychiatric treatment for a primary trauma- and stressor-related disorder diagnosis *Journal of Dual Diagnosis*
45. Panlilio LV, Burgess-Hull A, Feldman J, Rogers JM, Tyburski, M, **Smith KE**, Epstein DH (2024) Activity space during treatment with medication for opioid-use disorder: Relationships with personality, mood, and drug use. *Journal of Substance Use and Addiction Treatment*
46. **Smith KE***, Rogers JM, Sharma A, McCurdy CR, Weiss ST, Dunn KE, Feldman JD, Kuntz MA, Mukhopadhyay S, Raju KSR, Taylor RK, Epstein DH (2023) Responses to a “typical” morning dose of kratom in people who use kratom regularly: A direct-observation study. *Journal of Addiction Medicine*
47. **Smith KE***, Panlilio LV, Feldman JD, Grundmann O, Dunn KE, McCurdy CR, Garcia-Romeu A, Epstein DH (2024). Ecological momentary assessment of self-reported kratom use, effects, and motivations among US adults. *JAMA Network Open*

48. Zamarripa, CA, Spindle, TR, Panlilio, LV, Strickland, JC, Feldman, JD, Novak, MD, Epstein, DH, Dunn, KE, McCurdy, CR, ...**Smith KE*** (2024) Effects of kratom on driving: A cross-sectional, ecological momentary assessment, and simulated driving study. *Traffic Injury Prevention*
49. Bergeria CL, Gipson CD, **Smith KE**, Stoops WW, Strickland JC (2024) Opioid craving does not incubate over time in clinical research: Is the preclinical incubation of craving model lost in translation? *Neuroscience and Behavioral Reviews*
50. Hill K, Grundmann O, **Smith KE**, Stanciu CN (2024) Prevalence of kratom use disorder among kratom consumers. *Journal of Addiction Medicine*
51. Rogers JM, Weiss ST, Epstein DH, Grundmann O, Hill K, **Smith KE*** (2024) Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amounts versus frequency. *Drug and Alcohol Dependence*
52. Rogers JM, Colvin K, Epstein DE, Grundmann O, McCurdy CM, **Smith KE*** (2024). Growing pains with kratom: Experiences discussed in subreddits contrast with satisfaction expressed in surveys. *Frontiers in Pharmacology*
53. Hill K, Grundmann O, Panlilio L, Epstein DE, **Smith KE*** (2024) Use of cannabinoids by people who consume kratom in the United States. *Journal of Addiction Medicine*
54. Hill K, Rogers JM, Grundmann O, Epstein, DH, **Smith KE*** (2024) At least four “strains” of kratom consumers in the United States: Latent-class analysis of motivations for kratom use. *The American Journal of Drug and Alcohol Abuse*
55. **Smith KE***, Panlilio LV, Sharma A, McCurdy CR, Feldman JD, Mukhopadhyay S, Raju KSR, Kuntz MA, Hill K, Epstein DH (2024) Time course of kratom effects via ecological momentary assessment by product type, dose amount, and assayed alkaloid content. *Drug and Alcohol Dependence*
56. Mun CJ, Epstein DH, Panlilio LV, Dunn KE, Thrul J, McCurdy CM, **Smith KE*** (2025) Kratom (*Mitragyna Speciosa*) use for pain management: Insights from cross-sectional and ecological momentary assessment data. *Journal of Pain*, 26, 104726
57. **Smith KE***, Feldman J, Freinberg C, Shade S, Grundmann O (2025) Systematic review of clinical case reports involving tianeptine products: “Gas station heroin” hype or fact? *Current Addiction Reports*
58. Sharma A, **Smith KE**, Kuntz MA, Berthold EC, Elashkar OI, Guadagnoli N, Raju KSR, Mukhopadhyay S, Panlilio LV, Epstein DH and McCurdy CR (2025) Chemical analysis and alkaloid intake for kratom products available in the United States. *Drug Testing and Analysis*
59. Hill K, Boyer EW, Grundmann O, **Smith KE*** (2025) De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl products. *Drug and Alcohol Dependence*
60. **Smith KE***, Kanumuri Raju KSR, Sharma A, Rattenni R, LeComte R, McCurdy CR, Boyer EW, Strain EC (2025) Complicating factors surrounding concurrent use of kratom and a novel 7-hydroxymitragynine product among a participant enrolled in a kratom clinical trial. *Journal of Addiction Medicine*
61. Piercey CJ, Cameron J, Ahern, R, Packwood I, Bruning C, Henry D, Ruehrmund J, Weldon K, **Smith KE**, Karoly HC (2025) Kratom use among ethnobotanical tea bar patrons in Colorado: Subjective drug effects, adverse reactions, and perceived benefits of use. *Drug and Alcohol Dependence Reports*
62. Herberholz ES, Wolchok RE, Rogers JM, Selenou-Yemgang S, Beckwith BD, **Smith KE**, Epstein DH (2025) Latent classes of adverse childhood experiences (ACEs) and adult substance-use problems and psychosocial outcomes: complex and heterogenous associations. *International Journal of Mental Health and Addiction*
63. **Smith KE***, Hill K, Bergeria CL, Strickland JC (2025) Tianeptine products: Public health threat or niche substance use? *Journal of Psychoactive Drugs*
64. Reif B, Adkins A, Boyer EW, Kanumuri Raju KSR, Sharma A, **Smith KE*** (2025) Substance use disorder following consumption of a novel 7-hydroxymitragynine product. *Journal of Addiction Medicine*
65. Hill K, Anderson A, Sharma A, Kanumuri Raju KSR, Mukhopadhyay S, Veltri C, **Smith KE**, McCurdy CR, Grundmann O (2025) Diversification of kratom in US markets: Results form an online survey and chemical assay of products. *Substance Use and Misuse*.
66. Mun CJ, Timmons P, Panlilio LV, Verrico CD, Thomas YT, Zamarripa AC, Epstein DH, **Smith KE*** (2025) Is bedtime use of kratom (*Mitragyna speciosa*) a sleep aid or disruptor?: Examining its daily effects and individual differences. *Experimental and Clinical Psychopharmacology*
67. Pierce-Messick Z, **Smith KE**, Acuff SF, Reed DD, Epstein DH, Strickland JC (2025) Association of behavioral economic demand for kratom and DSM-5 use disorder: Quantity and likelihood-based demand approaches. *Addictive Behaviors Reports*
68. Kowalczyk WJ, **Smith KE**, Rogers JM, Bertz J, Epstein DH (Under Review) Demographics and self-perceptions of the broad population of the involuntarily celibate: They are more than just incels. *The Journal of Sex Research*
69. Piercey CJ, Bunch J, Cameron J, Ahern, R, Packwood I, Bruning C, Henry D, Ruehrmund J, Weldon K, Bunch J, **Smith KE**, Karoly HC (Under Review) Characteristics of adverse reactions to kratom and implementation of harm reduction strategies in a sample of ethnobotanical tea bar patrons in Colorado
70. Singh D, Mathandaver D, Müller CP, **Smith KE** (2025) Kratom (*Mitragyna speciosa*) as a replacement for alcohol among a sample of Malaysian adults with a history of alcohol use problems

71. [Hill K](#), Boyer EW, **Smith KE*** (2025) Clinically characterizing US adults who use kava or kratom: Substance use disorder assessment challenges for increasingly popular botanical products. *Drug and Alcohol Dependence Reports*
72. Timmons P, [Hill K](#), **Smith KE**, Riley A, Mun CJ (In Press) Akuamma seed (*Picralima nitida*) use in the US: Findings from a web-based survey
73. Epstein DH, Stull S, **Smith KE** (Under Review) Drug use without addiction in people with “a stake in the conventional life”: Lessons from an online pilot test of a classic sociological concept
74. [Hill K](#), [Piercy CJ](#), Karoly H, **Smith KE*** (Under Review) Kava (*Piper methysticum*) consumption patterns and conceptualizations: Results from an online survey of experienced consumers
75. **Smith KE**, Zeilinger N, Rattenni R, Feldman J, Boyer EW, Zamarripa A* (Under Review) Toward an understanding of 7-hydroxymitragynine (7-OH) products: Initial characterization of use patterns and consumer perceptions
76. Kanumuri Raju KSR, Sharma A, **Smith, KE**, Zeilinger N, McCurdy CR (In Preparation) UPLC-MS/MS-based quantification of major kratom alkaloids and metabolites in human plasma and its application to clinical samples analysis
77. [Hill K](#), [Piercy CJ](#), Epstein DH, Rattenni R, Zeilinger N, Boyer EW, Zamarripa A, **Smith KE*** (Under Review) Consumer Perspectives on Policy and Marketing for Novel 7-hydroxymitragynine (7-OH) Products: Regulation Is Recommended over Prohibition
78. [Piercy CJ](#), [Hill K](#), **Smith, KE**, Epstein DH, Rattenni R, Zeilinger N Boyer EW, Zamarripa A (In Preparation) Use or misuse?: An initial characterization of 7-hydroxymitragynine (7-OH) product experiences

Book Chapters, Monographs

1. **Smith KE**, Grundmann O, Swogger MT, Garcia-Romeu A (2023) Kratom (*Mitragyna speciosa*): Pharmacology and Use of a Naturally Occurring Atypical Opioid. *The Oxford Handbook of Opioids and Opioid Use Disorder, 1st edition*.
2. **Smith KE***, Grundmann O, Singh D (In Press) Kratom-related Physical Dependence and Addiction (Elsevier) *Kratom*
3. Durkin R, Grundmann O, **Smith KE** (In Press) Regulation and policy regarding kratom-derived dietary supplements and direct-to-consumer sales (Elsevier) *Kratom*

Letters, Correspondence

1. Grundmann O, Babin JK, Henningfield JE, Garcia-Romeu A, Kruegel AC, Prozialeck WC, Raffa RB, Singh D, and **Smith KE** (2021). Kratom use in the United States: a diverse and complex profile. *Addiction*, 116 [Letter to the Editor]
2. Stull SW[±], **Smith KE**[±], Vest N, Effinger DP, and Epstein DH (2021). Potential value of the insights and lived experiences of addiction researchers with addiction. *Journal of Addiction Medicine* [Commentary]
3. Strickland JC and **Smith KE** (2021) Comment on Heilig et al.: The centrality of the brain and the fuzzy line of addiction. *Neuropsychopharmacology*, 46, 1703-1704 [Research Highlight]
4. Grundmann O, McCurdy CR, Singh D, **Smith KE**, Swogger MT (2022). The pharmacology of kratom and its alkaloids. *Frontiers in Pharmacology* [Editorial].
5. **Smith KE***, Dunn KE, Epstein DH, [Feldman J](#), Garcia-Romeu A, Grundmann O, Henningfield J, McCurdy CR, [Rogers JM](#), [Schriefer D](#), Singh D, Weiss (2022) Need for clarity and context in case reports on kratom use, assessment, and intervention *Substance Abuse*, [Letter to the Editor]
6. **Smith KE*** (2022) Disease and decision. *Journal of Substance Abuse Treatment*, [Commentary]
7. **Smith KE***, Sharma A, Grundmann O, McCurdy C (2023). Kratom alkaloids: A blueprint? *ACS Chemical Neuroscience* [Invited Viewpoint]
8. Henningfield JE, Chawarski MC, Garcia-Romeu A, Grundmann O, Harun N, Hassan Z, McCurdy CR, McMahon L, Sharma A, Shoaib M, Singh D, **Smith KE**, Swogger MT, Vicknasingam B, Walsh Z, Wang D, Huestis MA (2023) Kratom withdrawal: Summary and conclusions of a virtual scientific forum. *Drug and Alcohol Dependence Reports* [Commentary]
9. Grundman O, Garcia-Romeu A, McCurdy CR, Sharma A, **Smith KE**, Swogger MT, Weiss ST (2023) Not all kratom is equal: the important distinction between native leaf and extract products. *Addiction* [Letter to the Editor]
10. McCurdy CR, Sharma A, **Smith KE**, Veltri, C, Weiss ST, White C, Grundman O (2024) An update on the clinical pharmacology of kratom: uses, abuse potential and future considerations? *Expert Review of Clinical Pharmacology* [Invited Review]
11. Grundmann O, **Smith KE**, Prozialeck WC, Veltri CA, Boyer E (2024) “Presence of kratom in opioid overdose deaths: Findings from coroner postmortem toxicological report” *Frontiers in Pharmacology* [Commentary]
12. Henningfield JE, Huestis MA, Grundmann O, **Smith KE** (2024) “Kratom safety and toxicology in the context of public health: Research needs to better inform regulation” *Frontiers in Pharmacology* [Review]
13. Acuff SF, Strickland JC, **Smith KE**, Field M (2024) Heterogeneity in choice models of addiction: The role of context. *Psychopharmacology* 241(9), 1757-1769 [Review]

14. **Smith KE***, Epstein DE, Weiss ST (2024) “Controversies in kratom use disorder” *Current Psychiatry Reports*, 1-10 [Invited Review]
15. **Hill K**, Grundmann O, **Smith KE**, Stanciu CN (2024) “Response to Gorelick” *Journal of Addiction Medicine* [Invited Response]
16. **Smith KE**, Boyer EW, Grundmann O, McCurdy CR, Sharma A (2025) “The rise of novel, semi-synthetic 7-hydroxymitragynine products” *Addiction* [Letter to the Editor]

Google Scholar H Index: 25

Media Releases or Interviews

Print/Online

- | | |
|------|---|
| 2018 | <i>Clinical Psychiatry News</i> , Randy Dotinga “For Some SUD Patients, Kratom May be a Self-treatment Tool” |
| 2022 | <i>Filter</i> , Doug Johnson “People’s Reasons for Using Kratom are Rapidly Diversifying” |
| 2022 | <i>Addiction Treatment Forum</i> , Barbara Goodheart “Lived Experience: A Refreshing New Voice” |
| 2022 | <i>VICE</i> , Manisha Krishnan “Gas Station Heroin’ is Causing Intense Withdrawals: It’s Legal in Most States” |
| 2023 | <i>The Messenger</i> , Sheila Baylis “Herbal Supplement Kratom is Being Bought and Sold in a ‘Wild West’ Marketplace” |
| 2024 | <i>Los Angeles Times</i> , Emily Alpert Reyes “Kratom products have gone unregulated in California, unnerving both fans and critics |
| 2024 | <i>Natural Products Insider</i> , Josh Long “Kratom groups, researchers sound alarm over 7-hydroxymitragynine products” |
| 2024 | <i>Bloomberg</i> , Fiona Rutherford & Immanuel John Milton “FDA pulls back its study into kratom plant’s effects” |
| 2024 | <i>The Guardian</i> , Shayla Love, “The wellness drink for sober people that some say they can’t stop drinking” |
| 2024 | <i>The New York Times</i> , Jan Hoffman “Rethinking addiction as a chronic brain disease” |
| 2024 | <i>Bloomberg</i> Fiona Rutherford & Immanuel John Milton “Kratom appears safe in early FDA study that excluded popular drinks” |
| 2024 | <i>Bangkok Post</i> “Kratom now a \$1-billion industry in US” |
| 2024 | <i>Dallas Morning News</i> Hojun Choi, “Kratom advocates says illegal, synthetic products are being sold in North Texas” |
| 2024 | <i>SupplySide Supplement Journal</i> Hank Schultz, “Kratom experts raise 7-OH alarm-again” |
| 2025 | <i>Johns Hopkins Magazine</i> , Ashley Stimpson, “Unknown Substance: Assistant Professor Kirsten Smith has become a leading voice on the herbal supplement kratom |
| 2025 | <i>PS</i> Chandler Plante, “TikTokers are sounding the alarm on kratom-but what is it?” |
| 2025 | <i>Missouri Independent</i> , Rebecca Rivas “FDA warns Kansas City manufacturer it is marketing illegal pain-relieving pills” |
| 2025 | <i>Supply Side Supplement Journal</i> Han Schultz, “FDA moves against 7-OH products” |
| 2025 | <i>New York Times</i> , Christina Jewett “Kennedy announces plan to restrict some kratom products” |
| 2025 | <i>The Wall Street Journal</i> , Sumathi Reddy “What you need to know about kratom” |
| 2025 | <i>Forbes</i> , Andrew DeAngelo “The science behind the fight over 7-OH” |
| 2025 | <i>CNN</i> , Kristen Rogers “Why a drink called Feel Free has many saying they’re trapped in addiction, debt, and rehab |
| 2025 | <i>The Kansas City Star</i> , David Hudnall “It’s addictive, and it’s everywhere’: KC company’s pills hook users across US” |
| 2025 | <i>The Pitch</i> , Joe Elliott “ Inside the kratom industry’s 7-OH tug of war between profits and public safety” |
| 2025 | <i>GQ</i> , Samantha Leach “How kratom, formerly known as ‘gas station heroin,’ went mainstream |
| 2025 | <i>The Guardian</i> , Xi Chen “From bank robber to scholar: the Knoxville dropout fighting to challenge how we see addiction |
| 2026 | <i>High Times</i> , Skye Hawthorne “The fight over 7OH is splitting the kratom industry” |

Podcasts

- | | |
|------|--|
| 2021 | <i>Kratom Science</i> hosted by Brian Gallagher, “Dr. Kirsten Smith of National Institute on Drug Abuse” |
| 2022 | <i>Psychoactive</i> hosted by Ethan Nadelmann, “Kirsten Smith on Kratom” |
| 2022 | <i>The Addiction Psychologist</i> hosted by Samuel Acuff and Noah Emery, “Kirsten Smith and Kratom” |
| 2022 | <i>Kratom Science</i> hosted by Brian Gallagher, “Dr. Kirsten Smith of NIDA Returns” |
| 2024 | <i>AirTalk</i> hosted by Larry Mantle (Los Angles NPR 89.3 FM) “...And a Look into Addiction” |

- 2025 *The Addiction Psychologist* hosted by Samuel Acuff and Noah Emery, “Kirsten Smith and Kratom Part II”
 2026 *SMART Policy Podcast* hosted by Jeremy Kourvelas, “What the Brain Disease Model of Addiction Gets Right and What it Misses”
 2026 *American Society of Addiction Medicine (ASAM) Practice Perils*, hosted by Dr. Stephan Taylor, “Kratom and 7-OH: What Clinicians Need to Know”

Television/Video

- 2023 NewsNation “Gas station heroin’ is addictive, and in some cases, deadly”
 2023 ABC WMAR “Maryland man’s death linked to kratom; herbal substance center of heated debate”
 2024 NBC WBIR “From robbing banks to becoming a Johns Hopkins professor: Knoxvilleian hopes to help others by studying addiction”
 2025 NBC WBIR “What is kratom? Knoxville police officer accused of shoplifting kratom while on duty: A professor at Johns Hopkins University studies kratom, and says a new form, 7-OH, acts only on opioid receptors, raising substance abuse concerns”

Popular Writing, Invited

- 2022 CLOSLER Johns Hopkins Medicine “Afraid to Tell the Truth”
 2022 The American Psychological Association Division 50 *SoAP Box* Newsletter-Clinical Translation Column “Cucumbers and Pickles”

FUNDING

Extramural Funding

- 6/1/2021 Real-world momentary assessment of kratom use and laboratory-based observed cessation accompanied by product assays: Toward an interdisciplinary characterization of kratom use and pharmacology.
 K99 DA055571-01
 Total Direct Costs: NA (Due to award being given to NIDA IRP postdoctoral fellow)
 *Note that NOA is not given for grants awarded to IRP fellows.
 Role: Principal Investigator
 Impact Score: 20
- 4/1/2024 Real-world momentary assessment of kratom use and laboratory-based observed cessation accompanied by product assays: Toward an interdisciplinary characterization of kratom use and pharmacology.
 R00 DA055571-02
 Total Costs: \$747,000
 Role: Principal Investigator
 Impact Score: 20
- 10/1/2024 Mentoring in advanced mHealth technologies and machine learning for HIV/drug abuse research
 DA037109-10 Subaward
 Total Direct Costs: \$18,518
 PI: Edward Boyer
- 9/15/2025 Evaluating kratom extract using a human drug development methodology: Single ascending dose safety and tolerability-human abuse potential
 1R01 DA061809-01
 Total Direct Costs: \$3,623,143
 Role: Principal Investigator
 Impact Score: 22
 Notice of Award: 9/15/2025
- 2/12/2025 Momentary and Longitudinal Effects of Kratom Use in Adults with Chronic Pain: A 12-Month EMA-Burst Study with Product Assays
 1R01DA064929-01

Total Direct Costs: \$2,478,443
Role: Multiple Principal Investigator
Impact Score: 41

Educational Intramural Funding

03/01/2017 Alternative psychoactive substances: Prevalence and emerging trends in a sample of drug-using individuals enrolled in community-based treatment
University of Louisville Graduate Student Research Fund Grant
Total Direct Costs: \$1,000
Indirect Costs: \$500
Role: Co-Investigator

CLINICAL ACTIVITIES

Certification

Active Licensed Masters Social Worker (LMSW) Maryland; License #30641

EDUCATIONAL ACTIVITIES

Teaching

Classroom instruction

2018 (Spring) Teaching Practicum, Undergraduate and Graduate hybrid, Substance Use and Substance Use Disorders.
University of Louisville

Virtual classroom instruction

2019 (Spring) Adjunct Instructor, Psychopathology II for Clinical Practice, Graduate Course, University of Kentucky
2020 (Spring) Adjunct Instructor, Psychopathology II for Clinical Practices, Graduate Course, University of Kentucky.

Mentoring

Pre-doctoral Research Mentees

2019-2024 Jeffrey M. Rogers, B.A., B.S., enrolled Clinical Psychology Doctoral Student, Pre-doctoral Trainee (NIDA DA031098), San Diego State University and the University of California San Diego
2020-2022 Salma Pont-Fernandez, B.S., Postbaccalaureate Training Fellow, NIDA IRP
2019-2022 Destiny Schriefer, B.A., enrolled Master of Science Candidate in Epidemiology, the Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
2021-2023 Jeffrey Feldman, B.S., Postbaccalaureate Training Fellow, NIDA IRP
2022-2025 Katherine Hill, M.P.H., enrolled Doctoral student, Yale School of Public Health, Department of Epidemiology of Microbial Diseases
2024-2025 Cianna Piercey, B.A., enrolled as Doctoral student in, Colorado State University Clinical Psychology Program (Ongoing mentorship in kratom data collection; publications forthcoming)

PROFESSIONAL ACTIVITIES

Appointments and Editorial Activities

2019-2022 Non-physician Scientist, National Institutes of Health Institution Review Board
2021-2022 Guest Associate Editor, *Frontiers in Pharmacology* Special Issue: The Pharmacology of Kratom and Its Alkaloids
2022-2024 Editorial Board, *Experimental and Clinical Psychopharmacology*
2022-Present Editorial Board, *Substance Abuse: Research and Treatment*
2022-Present Section Editor, *Current Addiction Reports*
2022-Present Consulting Editor, *Experimental and Clinical Psychopharmacology*
2023-Present Editorial Board, *Neuropsychopharmacology-Digital Psychiatry and Neuroscience*
2025-Present Editorial Board: *Substance Abuse Treatment, Prevention, and Policy*

Journal Peer Review Activities

2017-2018 Journal of Ethnopharmacology

2017-2018	Substance Abuse, Treatment, Prevention and Policy
2017-2025	Journal of Psychoactive Drugs
2018	Journal of Pain Research
2018-2024	Addiction
2018-2025	Drug and Alcohol Dependence
2019	Journal of Correctional Healthcare
2019	The American Journal of Public Health
2019	Tobacco Use Insights
2019-2024	The American Journal of Drug and Alcohol Abuse
2019-Present	Substance Abuse: Research and Treatment
2020	BMJ Open
2020	International Journal of Drug Policy
2020	Journal of Cannabis Research
2020	Alcohol and Alcoholism
2020	American Journal of Preventive Medicine
2020-Present	Substance Use and Misuse
2020-2021	Experimental Neurology
2020-2025	Experimental and Clinical Psychopharmacology
2021	Annals of Medicine
2021	Expert Opinion on Drug Metabolism and Toxicology
2021	Drug and Alcohol Dependence Reports
2021-2024	Journal of Addiction Medicine
2022	International Journal of Medical Sciences
2022-2025	JAMA
2022-Present	Current Addiction Reports
2023	Life Sciences
2023	The American Journal on Addictions
2023-Present	JAMA Network Open
2024	Harm Reduction Journal
2024	Psychopharmacology
2025	Social Science and Humanities Open
2025	Medical Reports

Advisory Committees, Review Groups/Study Sections

2022-2023	Advisor on NIDA “Kratom Drug Facts” webpage development.
2022-Present	The College on Problems of Drug Dependence, Travel Awards Committee
2023-2025	Organizing Committee Member International Symposium on the Science of Kratom
2024-Present	Dissertation Committee, KJ Jannie, DrPH Candidate (HPM-QPS), Johns Hopkins University
2024-Present	Johns Hopkins University Department of Psychiatry and Behavioral Sciences, Strategic Planning Committee: Expand Research Activities
2024-Present	NIH Early Career Reviewer Program
2025-Present	Dissertation Committee, Cianna Piercey, Clinical Psychology Doctoral Candidate, Colorado State University

Professional Societies

2014-2016	Member, National Association of Social Workers
2015-2016	Member, Students for a Sensible Drug Control Policy
2016-2019	Member, Sociologists for Women in Society
2017-2019	Member, Society for Social Work and Research
2017-2021	Member, American Society of Criminology
2017-Present	Member, Academic Consortium on Criminal Justice Health
2018-Present	Regular Member, College on Problems of Drug Dependence
2020-Present	Member, American Psychological Association <ul style="list-style-type: none"> • APA Division 28-Psychopharmacology & Substance Use Member, Executive Board • APA Division 50- Society of Addiction Psychology Member
2021-Present	Member, American Society of Addiction Medicine

2023-Present Member, International Society for Substance Use Professionals
 2023-Present Member, Doctors for Drug Policy Reform
 2024-Present Member, Society for the Study of Addiction
 2025-Present Member, National Association of Social Workers #886968163

National Session Chair

2018 “Is there a downside? Harm reduction”, 81st College on Problems on Problems of Drug Dependence Annual Meeting, Oral Session Co-Chair
 2021 “Addiction researchers with their own lived experiences of addiction: Implications for the science, the scientists, and the public”, 83rd College on Problems of Drug Dependence Annual Meeting, Forum Co-Chair.
 2022 “From bench to bedside to policy: Updating our understanding of kratom” 84th CPDD Annual Meeting, Symposium Chair
 2023 “The tightrope of substance abuse potential: The preclinical and clinical factors that make or break the scheduling of a substance, using kratom (*Mitragyna Speciosa*) as an example” 2023 Annual Meeting of the American College of Clinical Pharmacology, Symposium Co-Chair
 2025 “When does reductionism limit our perspective? The role of psychosocial and contextual determinants in substance use disorders” 87th College on Problems of Drug Dependence Annual Meeting, Symposium Chair

CONSULTANTSHIPS

2017-2018 Death penalty mitigation specialist-in-training consultant, Kentucky Department of Public Advocacy
 2023-2024 Scientific Advisor, The Kratom Coalition
 2023-2025 Consultant, International Plant and Herbal Alliance
 2024 Consultant, Barnes & Thornburg, LLP
 2024-Present Consultant, Kilpatrick Townsend & Stockton LLP
 2024-Present Consultant, Snell & Wilmer
 2025-2025 Consultant, Amin Wasserman Gurnani
 2025-2025 Consultant, Todd, Brown, Frost
 2025-2026 Consultant, Michael Best
 2025-Present Consultant, Pierce, Davis & Perritano LLP
 Pending Consultant, NIDA R01 “Reducing Stigma About Receiving Treatment for Opioid Use Disorder” (PI Sudie Back)

AWARDS & HONORS

2012-2013 Academic Excellence Scholarship, University of Kentucky
 2012-2013 Virginia Lane Award, full undergraduate scholarship, University of Kentucky Women’s Club
 2013-2014 Academic Excellence Scholarship, University of Kentucky
 2013-2014 Virginia Lane Award, full undergraduate scholarship, University of Kentucky Women’s Club
 2017 IDEA Festival competitive graduate student travel award
 2018 American Consortium on Criminal Justice Health (ACCJH) competitive doctoral travel award, Academic and Health Policy Conference on Correctional Health
 2018 Society for Social Work and Research competitive doctoral travel award
 2018 The College on Problems of Drug Dependence (CPDD) Travel Award for Early Career Investigators, competitive travel award
 2019 ACCJH competitive doctoral travel award, Academic and Health Policy Conference on Correctional Health
 2020 ACCJH competitive early career investigator travel award, Academic and Health Policy Conference on Correctional Health
 2021 NIDA-NIAAA R-13 competitive travel award, American Psychological Association Annual Convention
 2022 CPDD Female Opioid Research and Clinical Experts (FORCE) Junior Investigator, competitive travel award.
 2022 NIDA-NIAAA R-13 competitive travel award, American Psychological Association Annual Convention
 2024-2026 NIH/NIDA Loan Repayment Program (LRP) Award

INVITED TALKSRegional

- 12/2020 “So, what exactly is kratom?” National Institute on Drug Abuse IRP Clinical Rounds, Baltimore, MD
- 10/2021 “Is kratom use *misuse*?” National Institute on Drug Abuse IRP Fellows Research Lunch (Virtual)
- 10/2021 “Real-world momentary assessment of kratom use accompanied by product assays”, National Institute on Drug Abuse IRP, Translational Addiction Medicine Branch (Virtual)
- 11/2022 “Candid conversations about drug use, addiction, and recovery,” National Institute on Drug Abuse IRP (Virtual)
- 5/2023 “A Crash course on kratom,” Science for Non-Scientists, National Institute on Drug Abuse IRP (Baltimore, MD)
- 9/2023 “No longer niche: The rise and increasing popularity of kratom,” 14th Annual Johns Hopkins University Road to Recovery Annual Conference (Baltimore, MD)
- 10/2024 “How engagement with people with lived experience of addiction can inform innovative SUD interventions” I4SUD (Baltimore, MD)
- 12/2024 “Overview and update on kratom use in the United States: Implications for clinical practice, science, and policy” Johns Hopkins University Department of Psychiatry and Behavioral Sciences Seminar Series
- 5/2025 “Baltimore Neuroscience Community Spotlight and Discussion” University of Maryland, Baltimore
- 7/2025 “Kratom-derived Products and Public Health” Invited Generation Tomorrow Lecture, Johns Hopkins Medicine Division of Infectious Disease, Baltimore, Maryland
- 2/2026 “Update on kratom and 7OH: Implications for Policy” MedChi Opioid, Pain & Addiction Committee (virtual meeting)

National

- 03/2018 “Profile of kratom use among a sample of polysubstance users enrolled in residential drug treatment” Graduate Student Regional Research Conference, Louisville, KY
- 06/2018 “Kratom use patterns among opioid users in the United States: A novel form of harm-reduction?” CPDD Annual Meeting Media Forum (“blitz”), San Diego, CA
- 04/2021 “Introduction to kratom and its clinical implications”, START Kentucky Clinical Consortium (Virtual)
- 10/2021 “Clinical potential or clinical concern?: Characterizing the complexities of kratom use among humans” Department of Pharmacodynamics, Early Career Neuroscientist Seminar Series, Gainesville, FL (Virtual)
- 3/2022 “Kratom 101: Overview of the increasingly used plant-based product with mu opioid and other bioactive properties” University of Kentucky Neuroscientists Interested in Addiction Series, Lexington, KY.
- 3/2022 “Characterizing kratom use among humans: Implications for research and practice” University of Kentucky Department of Behavioral Science Grand Rounds Series, Lexington, KY.
- 8/2022 “Kratom: Should we be concerned?” ToxTime: United States Drug Testing Laboratories Webinar Series (Virtual)
- 11/2022 “Clinical issues for SUD treatment: Kratom” Yale School of Medicine, Division of Sciences, Department of Psychiatry (Virtual)
- 12/2022 “Clinical issues for SUD treatment: Kratom: Ecological momentary assessment preliminary findings” Yale School of Medicine, Division of Sciences, Department of Psychiatry (Virtual)
- 1/2023 “Neurodiversity in academia” panel speaker, Princeton University Wintersession (Virtual)
- 7/2023 “The emerging science and clinical perspective on kratom” International Plant and Herbal Alliance, Las Vegas, NV.
- 8/2023 “The role of journals in reducing stigma, and the role of people with lived experience in addiction research and publishing” International Society of Addiction Journal Editors (Boulder, CO)
- 11/2023 “Kratom: The unregulated and uncontrolled botanical product at the corner store” National Association of State Controlled Substances Authorities, Webinar (virtual)
- 12/2023 “Kratom Use Patterns and Clinical Trends in the United States” Congressional Briefing on Kratom Science and Policy (Washington, DC)
- 3/2024 “The curious case of kratom: Update on the science and clinical implications of this not-so-novel drug” Cure Addiction Now (Los Angeles, CA)
- 3/2024 “Current profile of kratom use in the United States: What you need to know.” Cure Addiction Now. National Webinar (virtual).

- 4/2024 “No longer novel: the enduring presence of kratom in the US and implications for clinical practice” Divisions of Addictions at Yale (DAY), Department of Psychiatry Seminar (Los Angeles, CA)
- 5/2024 “Researchers with Lived/Living Experience Involving Substance Use” Webinar, The College on Problems of Drug Dependence (virtual)
- 5/2024 “Ecological momentary assessment and lab-based pilot study of kratom use: What it tells us about consumption patterns and cognitive, physiological, and subjective effects” International Plant and Herbal Alliance (San Diego, CA)
- 8/2024 “Kratom consumers in the United States: What clinicians need to know” American Osteopathic Academy of Addiction Medicine (AOAAM), Opioid Research Network (ORN) Consortium National Webinar (virtual)
- 9/2024 “US clinical research on kratom: Overview of findings and policy implications” Congressional Briefing on Kratom Science and Policy (Washington, DC)
- 10/2024 “Overview of clinical research on kratom use in the United States” Arkansas Health Services Subcommittee of Public Health, Scientific Briefing (Little Rock, AK)
- 12/2024 “Implications of pre-mixed kratom and kava products” Utah Department of Agriculture and Food (Salt Lake City, UT)
- 2/2025 “Clinician-focused overview of kratom product use in the United States” New York Society of Addiction Medicine (virtual)
- 4/2026 “Kratom, 7-hydroxymitragynine, and mitragynine pseudoindoxyl: Research updates to better understand relative addiction risk profiles” University of Arizona Addiction Medicine Fellowship Guest Lecture (virtual)
- 4/2026* “Chasing kratom: Lessons learned from investigations into the real-world use of emerging psychoactive substances,” Brown University, Center for Alcohol and Addiction Studies Colloquium Series (Providence, RI)
- 5/2026* “Update on the diversification of kratom-derived products: 7-hydroxymitragynine, pseudoindoxyl, and beyond” American Osteopathic Academy of Addiction Medicine (AOAAM), Opioid Research Network (ORN) Consortium National Webinar (virtual)

International

- 3/2023 “Summary findings from investigation into kratom product use in the United States” side panel speaker, 66th United Nations Commission on Narcotic Drugs (virtual)
- 8/2024 “Kratom use trends in the United States of America” National Research and Innovation Agency (BRIN; Jakarta, Indonesia)
- 8/2024 “Kratom use in the United States” Indonesia Ministry of Health & Ministry of Trade (KEMENKES; Jakarta, Indonesia)
- 3/2025 “Update of findings from clinical research on kratom” side panel speaker, 67th United Nations Commission on Narcotic Drugs (Vienna, Austria)

SCIENTIFIC CONFERENCE PRESENTATIONS

Posters

1. **Smith KE**, Shalash S, Bunting A, Staton M, Walker R, Winston EM, and Pangburn K (April 2016) “Profile of synthetic drug users in corrections-based substance abuse treatment” Center for Clinical and Translational Science Spring Conference, Lexington, KY
2. **Smith KE**, Bunting A, Golder S, Hall MT, Higgins GE, and Logan TK (January 2018) “Prevalence and features of Social Security Disability Insurance utilization in a sample of women on community corrections” Society for Social Work Research Conference, Washington, DC
3. **Smith KE**, Bunting A, Golder S, Hall MT, Higgins GE, and Logan TK (April 2018) “Prevalence and correlates of disability among a sample of women on probation and parole” Academic and Health Policy Conference on Correctional Health, Houston, TX
4. **Smith KE** and Bunting A (March 2019) “Chemical bedfellows: Illicit use of prescription opioids and buprenorphine associated with methamphetamine use among a sample of polydrug users in Kentucky” Substance Use Research Day, Lexington, KY
5. **Smith KE** and Epstein DH (June 2020) “My name is peer-led recovery, and I need a moral inventory: Toward an ethics audit of recovery support services in the US” CPDD Annual Meeting (Virtual)
6. **Smith KE**, Rogers JM, Strickland, JC, and Epstein, DH (March 2021) “From trivia to trend: Use of tianeptine and other emerging drugs in an online sample of adults” Substance Use Research Event (Virtual)

7. **Smith KE**, Epstein DE, Rogers JM, and Strickland JC (June 2021) “Drug use without addiction in people with a ‘stake in the conventional life’: A classic ethnographic idea examined in nationwide crowdsourced data” CPDD Annual Meeting (Virtual)
8. **Smith KE**, Staton M, Archuleta A, and Winston E (April 2021) “Social dissatisfaction and suicidal ideation associated with high-risk opioid use following corrections-based drug treatment and reentry among a sample of adults in Kentucky” Academic and Health Policy Conference on Correctional Health (Virtual)
9. **Smith KE**, Dunn KE, Garcia-Romeu A, Grundmann O, Rogers JM, Swogger MT, Epstein DH (August 2021) “Psychological and substance use correlates of lifetime kratom use in a large online sample” American Psychological Association Annual Conference (Virtual)
10. **Smith KE**, Dunn, KE, McCurdy C, Rogers JM, Grundmann O, Strickland JC, Garcia-Romeu A, Epstein DH (November 2021) “The launch of an interdisciplinary set of studies on kratom, a widely used plant product with mu opioid and other bioactive properties”, NIDA-NIAAA Mini-Convention Frontiers in Addiction Research (Virtual)
11. Kaiser S, Rague J, **Smith KE**, and Weiss S (September 2021) “A secondary analysis of adverse events and naloxone administration in intentional kratom exposures from 2013-2020 using the Toxicology Investigators Consortium (ToxIC) registry” North American Congress of Clinical Toxicology” (Virtual)
Published abstract: *Clinical Toxicology*, 59, 1130-1131
12. **Smith KE**, Rogers JM, Dunn KE, McCurdy C, Strickland JC, Epstein DE (December 2021) “Opioid, cup of coffee, or antidepressant? The perceived functions of kratom among current and former users” American College of Neuropsychopharmacology Annual Meeting, San Juan, PR
Published abstract: *Neuropsychopharmacology*, 46, 431-432
13. **Smith KE**, Panlilio LV, Schriefer D, Leggio L, Phillips KA, Preston KL, Kramer MS, Fossler MJ, Shaham Y, Epstein DH (June 2022) “TRV734 as a potential medication for opioid use disorder: Protocol for a dose-finding pilot and proof-of-concept human laboratory study” CPDD Annual Meeting, Minneapolis, MN
14. **Smith KE**, Feldman, JD, Rogers JM, Dunn KE, McCurdy CR, Weis ST, Sharma A, Grundmann O, Epstein DH. (April 2023) “Effects after kratom self-administration of typical kratom dose among regular kratom-using adults” American Society of Addiction Medicine Annual Conference, Washington DC
15. **Smith KE**, Rogers JM, Sharma A, Zamarripa A, Weiss ST, Feldman JD, Spindle TR, Dunn KE, McCurdy CR, Epstein DH. (December 2023) “Physiological, subjective, and cognitive effects from a typical morning ‘dose’ of kratom among adults who use regularly: Findings from a direct-observation pilot study” American College of Clinical Neuropsychopharmacology Annual Meeting, Tampa, FL
16. **Smith KE**, Sharma A, Panlilio LV, McCurdy CR, Feldman JD, Epstein DE. (April 2024) “Ecological momentary assessment study of US adults who use kratom accompanied by product assay” Oxford International Conference on the Science of Botanicals, Oxford, MS
17. Weiss ST, Culbreth, R, Falise A, Aldy K, **Smith KE**, Wax PM, Campleman S, Brent J (September 2024) “The increasing evidence of serious adverse effects associated with the use of kratom” North American Congress of Clinical Toxicology
18. **Smith KE** & Hill K (April 2025) “Tianeptine “gas station heroin” products: Public health concern or niche substance use?” American Society of Addiction Medicine Annual Conference, Denver CO
19. **Smith KE**, Hill K, Piercey C, Karoly H (June 2025) “Twining of two botanicals: Clinical characteristics and assessment challenges of contemporaneous kava and kratom use among US adults” College on Problems of Drug Dependence, New Orleans, LA
20. **Smith KE**, Zamarripa A, Zeilinger N, Rattenni R, Boyer EW (Accepted; January 2026) “When a botanical breaks bad: Initial characterization of 7-hydroxymitragynine (7-OH) product use among US consumers” American College of Neuropsychopharmacology, Nassau Bahamas

Oral/Podium Presentations

21. **Smith KE**, Bunting A, Walker R, Hall MT, Grundmann O, Castillo O (June 2018) “Kratom use patterns among opioid users in the United States: A novel form of harm-reduction?”, CPDD Annual Meeting, San Diego CA
22. **Smith KE**, Tillson MD, Staton M, and Winston EM (April 2019) “Prevalence and correlates of past-year non prescribed buprenorphine use among a sample of adults entering Kentucky Department of Corrections drug treatment programs, Academic Health Policy Conference on Correctional Health, Las Vegas, NV.
23. Vest N, **Smith KE**, Stull S, Effinger D, Epstein DH, Cleveland H, Faulkner M (June 2021) Forum talk, “Experiential knowledge and the phenomenology of the addiction-remission continuum: Not a theory of anything, but a means to help modify theories of everything within addiction science”, CPDD Annual Meeting (Virtual)

24. Weiss S and **Smith KE** (April 2022) Focused Session, “Clinical characterization of kratom: Is it a craze or here to stay?” American Society of Addiction Medicine Annual Conference, Hollywood, FL
25. **Smith KE** (Chair), Grundmann O (Co-chair), McCurdy C, and Henningfield J, Dunn KE (Moderator) (June 2022) Full Symposium, “Real-world and clinical characteristics of kratom use” CPDD Annual Meeting, Minneapolis MN
26. Henningfield J, Huestis M, **Smith KE**, Kingston R (April 2023) Full Session, “Advancing Kratom Science: New Data on Kratom’s Pharmacology, Safety, Pharmacokinetics, Abuse Potential, And Real-World Surveys, Oxford International Conference on the Science of Botanicals, Oxford, MS
27. McCurdy C, Grundmann O, **Smith KE**, Weiss S (Co-Chair, August 2023) Full Symposium, “An Interdisciplinary Overview on the Increasing Clinical and Scientific Relevance of Kratom” American Psychological Association Annual Meeting, Washington DC
28. **Smith KE** (Co-chair), Henningfield J, Grundmann O (September 2023) Full Symposium, “Preclinical and clinical data on kratom as predictors for abuse liability” Annual Meeting of the American College of Clinical Pharmacology, Bellevue, WA
29. **Smith KE** (February 2024) “Findings from a direct-observation substudy of chronic kratom consumers” 3rd International Scientific Symposium on Kratom, Orlando, FL
30. **Smith KE** (February 2024) “A day in the life: Momentary and daily dosing patterns of US kratom consumers” 3rd International Scientific Symposium on Kratom, Orlando, FL
31. **Smith KE** (April 2024) Full Symposium, “Ecological momentary assessment and classification of kratom use patterns among US adults. Comprehensive Perspectives on Addiction Annual Meeting, Denver, CO
32. **Smith KE** (February 2025) “Current perspectives on kratom physical dependence and addiction” 4th International Scientific Symposium on Kratom, Orlando, FL
33. **Smith KE** (February 2025) “7OH uptake among kratom consumers: What we know from clinical trials screenings” 4th International Scientific Symposium on Kratom, Orlando, FL
34. ” 4th International Scientific Symposium on Kratom, Orlando, FL
35. **Smith KE**, Weiss S, Latham I, Levy R, Swart BB (April 2025) Focus Session, “Complexities and controversies in assessing, diagnosing, and managing kratom use” American Society of Addiction Medicine Annual Conference, Denver, CO
36. **Smith KE** & Boyer E (September 2025) Symposium “De facto opioids and the new addiction: 7-OH, ‘pseudo,’ and speciociliatine” 2025 North American Congress of Clinical Toxicology, Chicago, IL
37. Boyer EW, Smith KE, Babu KM (*March 2026) Symposium “Kratom, 7OH, and kratom combination products: It is far more than just a plant now” American College of Medical Toxicology Annual Scientific Meeting, Boston, MA
38. Hill K, **Smith KE**, Boyer E (*April 2026) Focus Session “Beyond kratom: Novel products containing 7-hydroxymitragynine, mitragynine pseudoindoxyl, MGM, and kava” American Society of Addiction Medicine Annual Meeting, San Diego, CA
39. Vest N, Ostacher M, **Smith K**, Hoaston T, Humphreys K (*June 2026) Symposium “Lived experiences across career stages: “Proving them wrong (and right)” CPDD Annual Meeting, Portland Oregon

COMMUNITY SERVICES

2012	Volunteer, Lexington Rescue Mission, Lexington KY
2012-2019	Volunteer Instructor, Hope Center Men’s Recovery Program, Lexington, KY
2013	Volunteer, AIDS Volunteers of America, Lexington, KY
2014	Volunteer, United Way of The Bluegrass, Lexington, KY
2014-2016	Guest speaker, University of Kentucky College of Social Work Undergraduate Program
2016-2017	Volunteer, Disability Resource Center, University of Louisville
2017	Volunteer, Bluegrass Reentry Council, Louisville KY
2018-2019	Volunteer Instructor, Hope Center Women’s Recovery Program, Lexington, KY
2020-2022	Volunteer, NIH Intramural Research Program “Postbac Poster Day” Judge
2021-2023	Volunteer, NIDA IRP Stigma Awareness & Reduction Team (StART), Baltimore, MD
2022-2023	Volunteer mentoring NIDA Undergraduate Research Internship Program
2023-2025	Division 28 Psychopharmacology & Substance Use Newsletter Editor
2022-present	Volunteer NIDA Speaker’s Bureau
2024-2026	Westminster, MD Board of Elections